Efficacy and safety of sunitinib in Chinese patients with imatinib-resistant or -intolerant gastrointestinal stromal tumors

Future Oncology

Volumn 8, Issue 5, 2012, Pages 617-624

  Li, Jian ^a   Gao, Jing ^a   Hong, Jinlin ^a   Shen, Lin ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

efficacy; gastrointestinal stromal tumors; imatinib intolerance; imatinib resistance; safety; sunitinib

Indexed keywords

IMATINIB; SUNITINIB;

ADULT; ARTICLE; BLEEDING; CANCER SURVIVAL; CHINESE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HAND FOOT SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT DURATION;

ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; DRUG RESISTANCE, NEOPLASM; FEMALE; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INDOLES; MALE; MUTATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; PYRROLES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84861737588     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.12.29     Document Type: Article

References (13)

1. Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P, Demetri G. Management of malignant gastrointestinal stromal tumours. Lancet Oncol. 3(11), 655-644 (2002).
2. Hirota S, Isozaki K, Moriyama Y et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279(5350), 577-580 (1998). (Pubitemid 28067289)
3. Heinrich MC, Corless CL, Duensing A et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299(5607), 708-710 (2003). (Pubitemid 36159485)
4. van Oosterom AT, Judson I, Verweij J et al.; European organisation for research and treatment of cancer soft tissue and bone sarcoma group. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A Phase I study. Lancet 358(9291), 1421-1423 (2001).
5. Demetri GD, Von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347(7), 472-480 (2002). (Pubitemid 34879334)
6. Verweij J, Casali PG, Zalcberg J et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial. Lancet 364(9440), 1127-1134 (2004). (Pubitemid 39296599)
7. Demetri GD, Huang X, Garrett CR et al. Novel statistical analysis of long-Term survival to account for crossover in a Phase III trial of sunitinib (SU) vs placebo (PL) in advanced GIST after imatinib (IM) failure. 2008 ASCO annual meeting. J. Clin. Oncol. 26(Suppl. 20), Abstract 10524 (2008).
8. George S, Blay JY, Casali PG et al. Continuous daily dosing (CDD) of sunitinib (SU) in pts with advanced GIST: Updated efficacy, safety, PK and pharmacodynamic analysis. 2008 ASCO Annual Meeting. J. Clin. Oncol. 26(Suppl. 20), Abstract 10554 (2008).
9. Blanke CD, Rankin C, Demetri GD et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J. Clin. Oncol. 26(4), 626-632 (2008). (Pubitemid 351264358)
10. Zalcberg JR, Verweij J, Casali PG et al.; EORTC soft tissue and bone sarcoma group, the Italian sarcoma group; Australasian gastrointestinal trials group. Outcome of patients with advanced gastrointestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur. J. Cancer 41, 1751-1757 (2005). (Pubitemid 41132637)
11. Reichardt P, Kang Y, Ruka W et al. Detailed analysis of survival and safety with sunitinib (SU) in a worldwide treatment-use trial of patients with advanced GIST. 2008 ASCO annual meeting. J. Clin. Oncol. 26(Suppl. 20), Abstract 10548 (2008).
12. Heinrich MC, Maki RG, Corless CL et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J. Clin. Oncol. 26(33), 5352-5359 (2008).
13. Shirao K, Nishida T, Doi T et al. Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate. Invest. New Drugs 28(6), 866-875 (2010).